design-poison-pill-provision

name	design-poison-pill-provision
description	Use when a board is considering adopting a shareholder rights plan (poison pill) to defend against an unsolicited takeover attempt or rapid stock accumulation — setting a defensible triggering threshold, a limited duration with a defined expiration, and a genuine, disclosed strategic rationale, rather than adopting an indefinite, low-threshold pill purely to entrench current management against any future challenge.
source	Delaware Court of Chancery precedent, including Moran v. Household International (1985) and Unocal Corp. v. Mesa Petroleum (1985); Institutional Shareholder Services (ISS) poison pill voting guidelines
tags	["law","corporate","poison-pill","shareholder-rights-plan","anti-takeover-defense","corporate-governance"]
related	["design-board-independence-standard","design-special-committee-process","audit-board-effectiveness"]

Design Poison Pill Provision

Set a defensible triggering threshold, a limited duration with a defined expiration, and a genuine, disclosed strategic rationale when adopting a shareholder rights plan (poison pill) — rather than adopting an indefinite, low-threshold pill purely to entrench current management against any future challenge.

Why This Is Best Practice

Adopted by: Delaware courts, beginning with Moran v. Household International (1985) and applying the Unocal Corp. v. Mesa Petroleum (1985) proportionality standard, have upheld poison pills as a legitimate board defensive tool while requiring the response be proportionate to a genuine, identifiable threat — and Institutional Shareholder Services' voting guidelines specifically evaluate a pill's threshold, duration, and the board's disclosed rationale when forming a voting recommendation on the plan. Impact: Poison pills structured with an indefinite term, an unusually low triggering threshold, or no genuine disclosed strategic rationale are documented to draw materially higher shareholder opposition and negative proxy advisory firm recommendations than pills structured with a limited duration, a standard threshold, and a clear rationale tied to a specific, identifiable threat — the difference in market and governance reception between these two structural approaches is well established. Why best: A poison pill's legal and governance legitimacy rests specifically on it being a proportionate response to a genuine threat, not an entrenchment device — a limited-duration pill with a standard threshold and disclosed rationale demonstrates this proportionality directly, while an indefinite, low-threshold pill without disclosed justification looks, and functions, more like blanket management entrenchment than a targeted defensive response.

Sources: Moran v. Household International, Inc., 500 A.2d 1346 (Del. 1985); Unocal Corp. v. Mesa Petroleum Co., 493 A.2d 946 (Del. 1985); Institutional Shareholder Services (ISS), poison pill and shareholder rights plan voting guidelines

Steps

Step 1: Set a standard, defensible triggering threshold

Set the pill's triggering threshold (the ownership percentage that activates the plan) at a level consistent with market standard practice — typically in the 10-20% range — since an unusually low threshold (well below market norms) is specifically scrutinized as evidence of an entrenchment purpose rather than a proportionate response to an actual takeover threat.

Step 2: Establish a limited duration with a defined expiration

Establish the pill with a limited term (commonly one to three years) with automatic expiration absent renewal, rather than an indefinite or unusually long duration — a limited term with defined expiration is specifically what proxy advisory firms and courts look for as evidence the pill is a temporary defensive measure rather than a permanent entrenchment tool.

Step 3: Document a genuine, specific strategic rationale

Document the board's specific, genuine rationale for adopting the pill at this particular time — a specific rapid-accumulation event, a hostile approach, or another concrete circumstance — rather than a generic, boilerplate justification that could apply to any company at any time.

Step 4: Consider requiring shareholder ratification for continuation

Consider a provision requiring shareholder ratification for the pill to continue beyond its initial term, or committing to put the pill to a shareholder vote at the next annual meeting, since this additional check is viewed favorably by proxy advisory firms and demonstrates the board isn't unilaterally entrenching the defense indefinitely.

Step 5: Reassess the pill's continued necessity as circumstances change

Reassess whether the pill remains necessary as the circumstances that motivated its adoption change — a pill adopted in response to a specific, since-resolved threat should be evaluated for continued necessity rather than allowed to persist by default once the original triggering circumstance has passed.

Rules

• Set the triggering threshold at a level consistent with market standard practice, not an unusually low threshold that signals entrenchment rather than proportionate defense.
• Establish a limited duration with defined expiration, not an indefinite or unusually long term.
• Document a specific, genuine strategic rationale tied to actual circumstances, not a generic, boilerplate justification.
• Reassess the pill's continued necessity as the circumstances that motivated its adoption evolve, rather than allowing it to persist indefinitely by default.

Examples

Proportionate pill responding to a genuine threat: A board adopts a poison pill with a standard 15% triggering threshold and a one-year term in direct response to a specific, rapid, unexplained accumulation of the company's stock by an activist investor — a proportionate, time-limited response to a genuine, identifiable circumstance, consistent with the disclosed rationale and structural features that receive favorable judicial and proxy advisory treatment.

Entrenchment-flagged pill drawing opposition (illustrative caution): A different board adopts a poison pill with an unusually low 5% threshold and no expiration date, with no specific disclosed rationale beyond general defensive preparedness. This structure draws a negative proxy advisory firm recommendation and significant shareholder opposition, illustrating the governance and market consequences of a pill structured without proportionality or a genuine, disclosed justification.

Common Mistakes

• Setting an unusually low triggering threshold — this is specifically scrutinized as evidence of an entrenchment purpose rather than a proportionate response to a genuine threat.
• Adopting an indefinite or unusually long duration without a defined expiration — limited duration is a key structural feature courts and proxy advisory firms look for as evidence of proportionality.
• Failing to document a specific, genuine strategic rationale — a generic justification that could apply to any company at any time undermines the pill's legitimacy as a targeted, proportionate response.
• Allowing the pill to persist indefinitely without reassessing whether the original triggering circumstance still applies — continued necessity should be actively reassessed, not assumed by default.

When NOT to Use

• For a private company with no publicly traded shares subject to accumulation risk — poison pills specifically address the risk of unsolicited accumulation of publicly traded shares.
• When the board has no genuine, identifiable threat or strategic rationale for adoption — adopting a pill purely as a precautionary measure with no specific triggering circumstance invites exactly the entrenchment scrutiny this practice is designed to avoid.
• For a jurisdiction other than Delaware, where the specific proportionality standard and case law discussed here may not directly apply — confirm the applicable jurisdiction's governing law before relying on this framework.

Legal disclaimer: This skill encodes professional best practices for educational purposes. It is not legal advice. Poison pill adoption carries significant fiduciary duty and litigation implications specific to the applicable jurisdiction — consult licensed corporate/M&A counsel before adopting or structuring a shareholder rights plan.